Basic Materials / ChemicalsNYSE
$23.18
+0.25 (+1.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $405.2M · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$817M
P/E
14.1x
↓EV/EBITDA
2.9x
↓ROE
18.8%
↑Gross Margin
29.8%
↑Debt/Equity
1.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
17.3%
FCF / Net income
4.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.17B · net income $48.7M · FCF $201.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $1.17B | $1.17B | $1.14B | $1.19B | $1.59B | $188.3M | $78.4M | $154.2M | $1.29B | $1.17B | $986.7M | $1.01B | $1.75B | — | — |
| Net Income | $48.7M | $48.7M | $62.4M | $54.3M | $64.2M | $82.5M | $66.2M | $61.0M | $49.3M | $48.7M | $40.9M | $39.8M | $13.6M | $546.5M | $395.9M |
| EBITDA | $409.0M | $409.0M | $481.9M | $446.5M | $470.3M | $519.5M | $456.1M | $457.5M | $458.4M | $488.4M | $464.7M | $440.5M | $794.2M | — | — |
| EPS | 1.38 | 1.38 | 1.77 | 1.54 | 1.82 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 29.8% | 29.8% | 36.9% | 32.5% | 23.7% | 234.6% | 483.1% | 246.0% | 29.3% | 34.4% | 39.7% | 38.0% | 42.6% | — | — |
| Operating Margin | 27.4% | 27.4% | 34.4% | 30.0% | 21.8% | 218.1% | 450.1% | 227.0% | 27.2% | 31.9% | 37.1% | 35.7% | 41.0% | — | — |
| Net Margin | 4.2% | 4.2% | 5.5% | 4.6% | 4.0% | 43.8% | 84.4% | 39.5% | 3.8% | 4.1% | 4.1% | 4.0% | 0.8% | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 1.55 | 1.55 | 1.45 | 1.43 | 1.37 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.65 | 3.65 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $201.7M | $201.7M | $436.0M | $405.2M | $409.6M | $327.3M | $336.4M | $407.1M | $396.3M | $468.5M | $-11.9M | $221.4M | $401.2M | — | — |
| Returns | |||||||||||||||
| ROE | 18.8% | 18.8% | 22.6% | 19.4% | 22.0% | — | — | — | — | — | — | — | — | — | — |
| Valuation | |||||||||||||||
| P/E | 14.13 | 14.13 | 12.97 | 14.18 | 12.94 | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 2.87 | 2.87 | 2.39 | 2.49 | 2.48 | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.16 | 3.16 | 2.93 | 2.75 | 2.84 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 2.7% | 2.7% | -4.6% | -25.3% | — | 140.1% | -49.2% | -88.0% | 9.6% | 18.9% | -2.0% | -42.4% | — | — | — |
| EPS Growth | -22.0% | -22.0% | 14.9% | -15.4% | — | — | — | — | — | — | — | — | — | — | — |
| Dividend Yield | 8.2% | 8.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
14.2%
EPS terminal req.
$2.06
Spread vs growth
-36.3%
5Y implied EPS CAGR
12.5%
EPS terminal req.
$2.49
Spread vs growth
-34.6%
10Y implied EPS CAGR
11.3%
EPS terminal req.
$4.01
Spread vs growth
-33.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.0%
Start / end P/E
12.5x → 16.8x
EPS bridge
1.77 → 1.38
Residual
-7.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.